President Trump’s changes are taking US healthcare in the right direction, asserts Megan McArdle in The Chicago Tribune. Allowing healthcare providers more leverage to negotiate will lower prices on Americans. The criticism that Trump isn't doing enough doesn't understand that US society, unlike in Europe, deeply scrutinizes many government choices. This includes healthcare, where many people like to be able to choose what products they can get. Europe’s healthcare is cheaper because providers negotiate and can say no to some products if prices are too high. The public prevents US providers from taking such stances.
US healthcare needs a lot more progress than what President Trump is offering, suggests Robert Reich in the American Prospect. Pharmacy companies have far too much leverage over US consumers. They have invested hundreds of millions to lobby for more influence. For example, they have gotten Congress to ban healthcare providers from negotiating drug prices. This is an essential part of lowering costs on Americans that Trump should tackle if he’s serious. Big pharma does everything it can to monetize US healthcare. Trump’s recent changes simply aren’t enough if he wants to make a meaningful difference.